Renal Cell Carcinoma

HUTCHMED and Innovent Biologics announced the NMPA acceptance of a New Drug Application for fruquintinib and sintilimab combination therapy. This targets advanced renal cell carcinoma patients who failed prior tyrosine kinase inhibitor treatment. Based on positive FRUSICA-2 trial results, it met its primary endpoint of progression-free survival. The therapy may address the unmet needs for second-line treatment, with ongoing research to expand its applications and indications in immuno-oncology.